Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: Results from the MONICA/KORA Myocardial Infarction Registry

Clinical Research in Cardiology

Volumn 103, Issue 8, 2014, Pages 655-664

  Amann, Ute ^a,b   Kirchberger, Inge ^a,b   Heier, Margit ^a,b   Golüke, Hildegard ^b   Von Scheidt, Wolfgang ^a   Kuch, Bernhard ^a,c   Peters, Annette ^b   Meisinger, Christa ^a,b  

^a KLINIKUM AUGSBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Hospital of Nördlingen   (Germany)

Author keywords

Acute myocardial infarction; Drug combination; Mortality; Secondary prevention drug therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONFOUNDING VARIABLE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; REGISTER; DRUG COMBINATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROCEDURES; SURVIVAL; SURVIVAL RATE; TIME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84904406594     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0688-0     Document Type: Article

References (35)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999-3054. doi:10.1093/eurheartj/ehr236
2. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart Federation and the Preventive Cardiovascular Nurses Association (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22):2458-2473. doi:10.1161/CIR.0b013e318235eb4d
3. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569-2619. doi:10.1093/eurheartj/ehs215
4. Sackner-Bernstein J (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28(11 Suppl 1):I19-I27
5. Gotto AM Jr, LaRosa JC (2005) The benefits of statin therapy - what questions remain? Clin Cardiol 28(11):499-503
6. Vanuzzo D, Pilotto L, Pilotto L, Mähönen M, Hobbs M, for the WHO MONICA Project (2000) Pharmacological treatment during AMIand in secondary prevention: the scientific evidence. Published by World Health Organization (WHO) and the WHO MONICA Project investigators 2000. http://www.thl.fi/ publications/monica/carpfish/appenda/evidence.htm. Accessed 4 Dec 2013
7. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task force on practice guidelines (Committee to Revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44(3):E1-E211
8. Zeymer U, Junger C, Zahn R, Bauer T, Bestehorn K, Senges J, Gitt A (2011) Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opin 27(8):1563-1570. doi:10.1185/03007995.2011.590969
9. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG, Canadian ACS Registries Investigators (2007) Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 154(6):1108-1115 (Pubitemid 350123528)
10. Bauer T, Gitt AK, Jünger C, Zahn R, Koeth O, Towae F, Schwarz AK, Bestehorn K, Senges J, Zeymer U, Acute Coronary Syndromes Registry (ACOS) investigators (2010) Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil 17(5):576-581. doi:10.1097/HJR.0b013e328338e5da
11. Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U (2010) The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96(8):604-609. doi:10.1136/hrt.2009.188607
12. Lahoud R, Howe M, Krishnan SM, Zacharias S, Jackson EA (2012) Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol 109(2):159-164. doi:10.1016/j.amjcard.2011. 08.024
13. Kirchmayer U, Di Martino M, Agabiti N, Bauleo L, Fusco D, Belleudi V, Arcà M, Pinnarelli L, Perucci CA, Davoli M (2013) Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case-control study in Italy. Pharmacoepidemiol Drug Saf 22(6):649-657
14. Kuepper-Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R, Schubert (2012) Association of long-term adherence to evidencebased combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data. Eur J Clin Pharmacol 68(10):1451-1460. doi:10.1007/s00228-012-1274-x
15. Gunnell AS, Einarsdóttir K, Sanfilippo F, Liew D, Holman CD, Briffa T (2013) Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart 99(18):1353-1358. doi:10.1136/heartjnl-2013-304348
16. Meisinger C, Hormann A, Heier M, Kuch B, Löwel H (2006) Admission blood glucose and adverse outcomes in non-diabetic patients with myocardial infarction in the reperfusion era. Int J Cardiol 113(2):229-235 (Pubitemid 44767578)
17. Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C (2008) 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985-2004). J Intern Med 264(3):254-264. doi:10.1111/j.1365-2796.2008.01956.x
18. Lee JH, Yang DH, Park HS, Cho Y, Jeong MH, Kim YJ, Kim KS, Hur SH, Seong IW, Hong TJ, Cho MC, Kim CJ, Jun JE, Park WH, Chae SC, Korea Acute Myocardial Infarction Registry Investigators (2010) Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J 159(6):1012-1019. doi:10.1016/j.ahj.2010.03.009
19. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA (2004) Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109(6):745-749 (Pubitemid 38222894)
20. Timoteo AT, Fiarresga A, Feliciano J, Pelicano N, Ferreira L, Oliveira JA, Serra J, Ferreira R, Quininha J (2006) Impact of combination medical therapy on mortality in patients with acute coronary syndromes. Rev Port Cardiol 25(12):1109-1118
21. Danchin N, Cambou JP, Hanania G, Kadri Z, Genè s N, Lablanche JM, Blanchard D, Vaur L, Clerson P, Guéret P, USIC 2000 investigators (2005) Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 150(6):1147-1153 (Pubitemid 41773515)
22. Gouya G, Reichardt B, Ohrenberger G, Wolzt M (2007) Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 22(3):145-149 (Pubitemid 46481324)
23. Pereira M, Araujo C, Dias P, Lunet N, Subirana I, Marrugat J, Capewell S, Bennett K, Azevedo A (2013) Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study. Eur J Prev Cardiol. doi:10.1177/2047487313494580
24. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, Allemand H (2010) Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 103(6-7):363-375. doi:10.1016/j.acvd.2010.05.003
25. Liosis S, Bauer T, Schiele R, Gohlke H, Gottwik M, Katus H, Sabin G, Zahn R, Schneider S, Rauch B, Senges J, Zeymer U (2013) Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 102(9):671-677. doi:10.1007/s00392-013-0581-2
26. Sinning JM, Asdonk T, Erlhöfer C, Vasa-Nicotera M, Grube E, Nickenig G, Werner N (2013) Combination of angiographic and clinical characteristics for the prediction of clinical outcomes in elderly patients undergoing multivessel PCI. Clin Res Cardiol 102(12):865-873. doi:10.1007/s00392-013-0599-5
27. Stark R, Kirchberger I, Hunger M, Heier M, Leidl R, von Scheidt W, Meisinger C, Holle R (2014) Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clin Res Cardiol 103:237-245. doi:10.1007/s00392-013-0643-5
28. Yarzebski J, Granillo E, Spencer FA, Lessard D, Gurwitz JH, Gore JM, Goldberg RJ (2009) Changing trends (1986-2003) in the use of lipid lowering medication in patients hospitalized with acute myocardial infarction: a community-based perspective. Int J Cardiol 132(1):66-74. doi:10.1016/j.ijcard. 2007.10.055
29. Jernberg T, Johanson P, Held C, Svennblad B, Lindbäck J, Wallentin L, SWEDEHEART/RIKS-HIA (2011) Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 305(16):1677-1684. doi:10.1001/jama.2011.522
30. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC, National Heart, Lung, and Blood Institute (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363-2372 (Pubitemid 43947981)
31. Milonas C, Jernberg T, Lindback J, Agewall S, Wallentin L, Stenestrand U, RIKS-HIA Group (2010) Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol 105(9):1229-1234. doi:10.1016/j.amjcard.2009.12.032
32. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL, PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351(20):2058-2068
33. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX, CF/AHA Task Force (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on practice guidelines. Circulation 127(4):e362-e425. doi:10.1161/CIR.0b013e3182742c84
34. Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 103:173-182. doi:10.1007/s00392-013-0616-8
35. Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Störk S (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol 101(4):263-272. doi:10.1007/s00392-011-0388-y